Meeder Asset Management’s ImmunityBio IBRX Stock Holding History

Meeder Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-20,452	Closed	-$37.2K	–	550
2023 Q1	$37.2K	Buy	20,452 +1,100	+6%	+$3.42K	﹤0.01%	451
2022 Q4	$98.1K	Sell	19,352 -36,812	-66%	-$202K	0.01%	479
2022 Q3	$279K	Buy	56,164 +16,923	+43%	+$77.1K	0.02%	506
2022 Q2	$146K	Buy	+39,241	New	+$158K	0.01%	662
2021 Q2	–	Sell	-184	Closed	-$4K	–	2576
2021 Q1	$4K	Buy	+184	New	+$4.77K	﹤0.01%	1913
2020 Q4	–	Sell	-7,782	Closed	-$54K	–	2028
2020 Q3	$54K	Buy	+7,782	New	+$77.6K	﹤0.01%	942
2020 Q1	–	Sell	-2,024	Closed	-$8K	–	2406
2019 Q4	$8K	Sell	2,024 -2,568	-56%	-$4.37K	﹤0.01%	1626
2019 Q3	$6K	Buy	4,592 +3,060	+200%	+$3.8K	﹤0.01%	1697
2019 Q2	$2K	Sell	1,532 -1,100	-42%	-$1.27K	﹤0.01%	1861
2019 Q1	$4K	Buy	+2,632	New	+$3.31K	﹤0.01%	1439
2018 Q4	–	Sell	-1,370	Closed	-$5K	–	1749
2018 Q3	$5K	Buy	+1,370	New	+$4.33K	﹤0.01%	1329
2018 Q1	–	Sell	-952	Closed	-$4K	–	1636
2017 Q4	$4K	Buy	952 +575	+153%	+$2.72K	﹤0.01%	1361
2017 Q3	$2K	Hold	377	–	–	﹤0.01%	1455
2017 Q2	$3K	Sell	377 -1,328	-78%	-$5.74K	﹤0.01%	1324
2017 Q1	$6K	Hold	1,705	–	–	﹤0.01%	1008
2016 Q4	$10K	Buy	+1,705	New	+$11.4K	﹤0.01%	754

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

Meeder Asset Management's IBRX Position: Q2 2023 in Review

Meeder Asset Management sold out of ImmunityBio (IBRX) in Q2 2023, closing a stake of 20,452 shares — an estimated $37.2K sold.

Meeder Asset Management first reported a position in IBRX in Q4 2016 and held it in 16 quarters. The position peaked at $279K in Q3 2022. 117 funds tracked by Wall St. Rank hold IBRX as of Q2 2023.

Meeder Asset Management reported no remaining ImmunityBio position as of Q2 2023 after selling out during the quarter.
Meeder Asset Management sold 20,452 ImmunityBio shares in Q2 2023, an estimated $37.2K.
Meeder Asset Management first reported a position in ImmunityBio in Q4 2016 and held it in 16 quarters.
Meeder Asset Management's ImmunityBio position peaked at $279K in Q3 2022.
117 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2023.

Based on Meeder Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.